The majority of undesirable effects are dose dependent. The frequency and severity are most pronounced in the early phase of treatment and decline during continued treatment. Extrapyramidal reactions may occur, especially in the early phase of treatment.
In most cases these side effects can be satisfactorily controlled by reduction of dosage and/or use of antiparkinsonian drugs. The routine prophylactic use of antiparkinsonian drugs is not recommended. Antiparkinsonian drugs do not alleviate tardive dyskinesia and may aggravate it.
Reduction in dosage or, if possible, discontinuation of zuclopenthixol therapy is recommended. In persistent akathisia a benzodiazepine or propranolol may be useful. Blood and lymphatic system disorders Thrombocytopenia, neutropenia, leukopenia, agranulocytosis.
Immune system disorders Hypersensitivity, anaphylactic reaction. Endocrine disorders Hyperprolactinaemia. Increased appetite, weight increased. Decreased appetite, weight decreased. Metabolism and nutrition disorders Hyperglycaemia, glucose tolerance impaired, hyperlipidaemia.
Insomnia, depression, anxiety, nervousness, abnormal dreams, agitation, libido decreased. Psychiatric disorders Apathy, nightmare, libido increased, confusional state. Somnolence, akathisia, hyperkinesia, hypokinesia. Tremor, dystonia, hypertonia, dizziness, headache, paraesthesia, disturbance in attention, amnesia, gait abnormal.
Tardive dyskinesia, hyperreflexia, dyskinesia, parkinsonism, syncope, ataxia, speech disorder, hypotonia, convulsion, migraine. Nervous system disorders Neuroleptic malignant syndrome. Accommodation disorder, vision abnormal. Eye disorders Oculogyration, mydriasis.
Ear and labyrinth disorders Hyperacusis, tinnitus. Cardiac disorders Electrocardiogram QT prolonged. Vascular disorders Venous thromboembolism Respiratory, thoracic and medistianal disorders Nasal congestion, dyspnoea. Dry mouth. Salivary hypersecretion, constipation, vomiting, dyspepsia, diarrhoea.
Gastrointestinal disorders Abdominal pain, nausea, flatulence. Hepato-biliary disorders Cholestatic hepatitis, jaundice. Skin and subcutaneous tissue disorders Rash, photosensitivity reaction, pigmentation disorder, seborrhoea, dermatitis, purpura.
Musculoskeletal and connective tissue disorder Muscle rigidity, trismus, torticollis. Renal and urinary disorders Micturition disorder, urinary retention, polyuria. 6) Ejaculation failure, erectile dysfunction, female orgasmic disorder, vulvovaginal dryness.
Reproductive system and breast disorders Gynaecomastia, galactorrhoea, amenorrhoea, priapism. General disorders and administration site conditions Thirst, injection site reaction, hypothermia, pyrexia. 4). Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis have been reported with antipsychotic drugs – Frequency unknown.
Abrupt discontinuation of zuclopenthixol may be accompanied by withdrawal symptoms. The most common symptoms are nausea, vomiting, anorexia, diarrhoea, rhinorrhoea, sweating, myalgias, paraesthesias, insomnia, restlessness, anxiety, and agitation.
Patients may also experience vertigo, alternate feelings of warmth and coldness, and tremor. Symptoms generally begin within 1 to 4 days of withdrawal and abate within 7 to 14 days. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.